Association of Prior BNT162b2 COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection in Children and Adolescents During Omicron Predominance

Association of COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection by Time Since Vaccination and Delta Variant Predominance

(2022) Amadea Britton et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants

(2022) Emma K. Accorsi et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection

(2022) Victoria Hall et al.   NEW ENGLAND JOURNAL OF MEDICINE

Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022

(2022) Jill M. Ferdinands et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

Hospitalizations of Children and Adolescents with Laboratory-Confirmed COVID-19 — COVID-NET, 14 States, July 2021–January 2022

(2022) Kristin J. Marks et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5–11 Years and Adolescents Aged 12–15 Years — PROTECT Cohort, July 2021–February 2022

(2022) Ashley L. Fowlkes et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5–17 Years — VISION Network, 10 States, April 2021–January 2022

(2022) Nicola P. Klein et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Adolescents Aged 12–15 Years — United States, May 2021

(2021) Megan Wallace et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents

(2021) Robert W. Frenck et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study

(2021) Sara Y Tartof et al.   LANCET

Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age

(2021) Emmanuel B. Walter et al.   NEW ENGLAND JOURNAL OF MEDICINE

Community-Based Testing Sites for SARS-CoV-2 — United States, March 2020–November 2021

(2021) Mark F. Miller et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Children Aged 5–11 Years — United States, November 2021

(2021) Kate R. Woodworth et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

The Use of Test-negative Controls to Monitor Vaccine Effectiveness

(2019) Huiying Chua et al.   EPIDEMIOLOGY

Effects of imperfect test sensitivity and specificity on observational studies of influenza vaccine effectiveness

(2015) Michael L. Jackson et al.   VACCINE